FDA gives thumbs up to mini ICDs

Candace Stuart | | Cardiovascular Business | Heart Failure

The FDA approved the latest generation of Boston Scientific’s implantable cardiac devices.

Natick, Mass.-based Boston Scientific received the go-ahead to market devices that include its Dynagen Mini and Inogen Mini implantable cardioverter-defibrillators (ICDs) and Dynagen X4 and Inogen X4 cardiac resynchronization therapy-defibrillators (CRT-Ds). The company claims the Mini devices are 20 percent smaller by volume and 24 percent thinner than other devices. The X4 line of devices includes a six-year CRT-D warranty.

The devices are approved for patients with heart failure and those at risk of sudden cardiac death.

Candace Stuart, Contributor

Related Content

Medtronic using AI to identify more TAVR patients in need
Tirzepatide linked to significant weight loss, ‘impressive’ diabetes prevention after 3 years
Most heart failure patients miss out on guideline-recommended palliative care
CMS updates outpatient reimbursement policy for Barostim device
American Heart Association announces late-breaking research for Scientific Sessions 2024
Impella ECP confirmed to be safe for high-risk PCI—is FDA approval next?

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."